BioCryst Pharmaceuticals, Inc. (BCRX)
8.97
-0.05
(-0.55%)
USD |
NASDAQ |
May 18, 16:00
8.98
+0.01
(+0.11%)
After-Hours: 20:00
BioCryst Pharmaceuticals Research and Development Expense (Quarterly) : 59.26M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 6.713M |
| KalVista Pharmaceuticals, Inc. | 12.42M |
| Revolution Medicines, Inc. | 341.62M |
| Plus Therapeutics, Inc. | 2.865M |
| Perspective Therapeutics, Inc. | 20.25M |